FDA公布杭州民生滨江制药483检查报告,列设备清洁、OOS调查与GMP文件管理3项观察
FDA 483:杭州民生滨江制药有限公司
FDA公布杭州民生滨江制药有限公司的483检查报告,检查于2025年3月3日至7日进行,共列3项观察。观察一为标示已清洁的设备管道内检出原料药残留,且清洁验证未评估该管道;观察二指出第20240601号OOS调查认定化验员手套污染但无证据或数据支持,三批重新配样复测合格后放行。
近日,FDA 公布了杭州民生滨江制药有限公司(杭州市滨江区滨安路658号,FEI 3007438452)的483检查报告,检查5天,列3项观察。
这是一家口服固体制剂厂,杭州民生药业的全资子公司,片剂和胶囊,多个品种出口美国。检查报告里三件事各说一头:标着“已清洁”的设备管道里擦出药;三个批次检出 OOS,调查结论是化验员手套污染,却“没有证据或数据支持”,重新配样复测合格就放行;最重的一条在最后——QC 实验室的垃圾桶里有撕毁、丢弃的 GMP 文件,公司自己不知道。
图1 FDA 483 原件第1页(FEI 3007438452,2025年3月7日签发)
Inspection Details
检查基本信息
Firm / 企业
Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd. 杭州民生滨江制药有限公司
Address / 地址
658 Bin'An Road, Binjiang District(杭州市滨江区滨安路658号)
City / 城市
Hangzhou, Zhejiang, 310051 China(中国浙江杭州,310051)
FEI Number / FEI 号
3007438452
Dates of Inspection / 检查日期
2025年3月3日–3月7日
Type Establishment Inspected / 受检设施类型
Drug Manufacturer(药品生产企业)
Issued To / 收件人
Yuhang Gao, General Manager(高宇航,总经理)
District Office / 地区办公室
12420 Parklawn Drive, Room 2032, Rockville, MD 20857
Issued / 签发
2025年3月7日 检查员:Khoa Nathan V Tran;Lillian S Wu
说明:原件为 FDA 统一格式表格,全篇未印法规条款号。三项观察标题与 21 CFR 211.67(a)、211.192、211.22(d) 逐字对应,属编者对应,见文末译注①。
OBSERVATION 1
观察1:设备清洁(编者对应 21 CFR 211.67(a))
Equipment and utensils are not cleaned at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
设备与器具未按适当间隔清洁,以防止可能改变药品安全性、鉴别、效力、质量或纯度的污染。
Specifically, during the inspection, we observed residue (b)(4) in the (b)(4) duct of your (b)(4) (b)(4) (equipment ID # (b)(4)) which was labeled "cleaned". After analysis, your firm identified the residue to contain active pharmaceutical ingredient (b)(4) (b)(4). (b)(4) is non dedicated and is used to manufacture multiple drug products, including (b)(4) (b)(4) Tablets for the U.S. Additionally, your firm failed to assess the (b)(4) duct of your (b)(4) (b)(4) during your cleaning validation study.
具体而言,检查期间,我们观察到贵公司 (b)(4) (b)(4)(设备编号 (b)(4),标示为“已清洁”)的 (b)(4) 管道内有残留物 (b)(4)。经分析,贵公司确定该残留物含有活性药物成分 (b)(4) (b)(4)。该 (b)(4) 为非专用设备,用于生产多个药品,包括供美国市场的 (b)(4) 片。此外,贵公司在清洁验证研究中未对该 (b)(4) 管道进行评估。
OBSERVATION 2
观察2:OOS 调查(编者对应 21 CFR 211.192)
There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
批次或其任何组分未能符合其任一质量标准时,未进行彻底审查,无论该批次是否已经放行。
Specifically, your out-of-specification (OOS) investigation is not thorough and complete. For example, OOS investigation # 20240601 was initiated when (b)(4) residue tests yielded OOS results for three (3) batches (b)(4) Tablets:
具体而言,贵公司的不符合(OOS)调查不彻底、不完整。例如,第20240601号 OOS 调查的启动,是因为 (b)(4) 残留检测对三个批次的 (b)(4) 片得出 OOS 结果:
Batch # | Result |
|---|---|
(b)(4) | (specification: NMT (b)(4) ppm) |
(b)(4) | (b)(4) |
上表照录原件表格结构:灰色格为原件整块遮蔽的数据行;批号格内的蓝色手写为原件所有。
The investigation determined that the most likely root cause was glove contamination caused by analyst error. This root cause was not adequately supported with evidence or data. Instead, (b)(4) fresh sample solutions were prepared for each affected batch for retesting. The retest yielded passing results, and the batches were released.
该调查确定最可能的根本原因是化验员操作失误造成的手套污染。这一根本原因没有证据或数据充分支持。贵公司改为对每个受影响批次重新配制新鲜样品溶液进行复测。复测得出合格结果,批次被放行。
OBSERVATION 3
观察3:QC 部门职责与程序(编者对应 21 CFR 211.22(d))
The responsibilities and procedures applicable to the quality control unit are not fully followed.
适用于质量控制部门的职责与程序,未完全遵守。
Specifically, during the inspection, we observed torn and discarded GMP documents in the trash bin located in the QC laboratory. Your firm was unaware that these GMP documents were altered and discarded. GMP documents are not managed according to your procedures, document # 02-QA-2-001 and 02-QA-2-004.
具体而言,检查期间,我们在 QC 实验室的垃圾桶内发现被撕毁、丢弃的 GMP 文件。贵公司不知道这些 GMP 文件已被改动并丢弃。GMP 文件未按贵公司第02-QA-2-001号和第02-QA-2-004号程序管理。
图2 原件第2页:第3项观察与两位检查员的签字
来源:制药经理人 · mp.weixin.qq.com